Zai Lab (ZLAB) Stock Price, News & Analysis

Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Key Stats

• Today's Range: $35.91 to $37.83
• 50-Day Range: $26.27 to $38.35
• 52-Week Range: $13.48 to $39.77
• Volume: 1.22 million shs
• Average Volume: 773,874 shs
• Market Capitalization: $4.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.37
• Consensus Rating: Moderate Buy

Zai Lab Stock Analysis - MarketRank™

Zai Lab scored higher than 46% of companies evaluated by MarketBeat, and ranked 575th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Zai Lab has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zai Lab are expected to grow in the coming year, from ($2.58) to ($1.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zai Lab is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zai Lab is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zai Lab has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.40% of the float of Zai Lab has been sold short.

Short Interest Ratio / Days to Cover

Zai Lab has a short interest ratio ("days to cover") of 9.9.

Change versus previous month

Short interest in Zai Lab has recently increased by 1.15%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zai Lab does not currently pay a dividend.

Dividend Growth

Zai Lab does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.40% of the float of Zai Lab has been sold short.

Short Interest Ratio / Days to Cover

Zai Lab has a short interest ratio ("days to cover") of 9.9.

Change versus previous month

Short interest in Zai Lab has recently increased by 1.15%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.87

News Sentiment

Zai Lab has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Zai Lab this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for ZLAB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,495,143.00 in company stock.

Percentage Held by Insiders

13.88% of the stock of Zai Lab is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZLAB Stock Analysis - Frequently Asked Questions

How have ZLAB shares performed this year?

Zai Lab's stock was trading at $26.19 at the beginning of 2025. Since then, ZLAB stock has increased by 40.1% and is now trading at $36.69.
View the best growth stocks for 2025 here.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) posted its quarterly earnings results on Thursday, February, 27th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.19. The company had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative trailing twelve-month return on equity of 36.97% and a negative net margin of 76.14%.

When did Zai Lab IPO?

Zai Lab (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Meta Platforms (META), Advanced Micro Devices (AMD), Baidu (BIDU) and Home Depot (HD).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 4/03/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZLAB
• CIK: 1704292
• Web: www.zailaboratory.com
• Phone: 862161632588
• Fax: 86-21-6163-2570
• Employees: 1,950
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $47.37
• High Stock Price Target: $55.00
• Low Stock Price Target: $36.10
• Potential Upside/Downside: +29.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-334,620,000.00
• Net Margins: -76.14%
• Pretax Margin: -76.14%
• Return on Equity: -36.97%
• Return on Assets: -27.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.01
• Quick Ratio: 2.87

Sales & Book Value

• Annual Sales: $398.99 million
• Price / Sales: 10.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.05 per share
• Price / Book: 4.56

Miscellaneous

• Outstanding Shares: 109,628,000
• Free Float: 94,239,000
• Market Cap: $4.02 billion
• Optionable: Optionable
• Beta: 1.07